We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Italian Consortium Acquires Esaote

By HospiMedica staff writers
Posted on 31 Jan 2006
Print article
Banca Intesa (Milan, Italy) and the Bracco Group (Milan, Italy), a global leader in diagnostic imaging, have agreed to the sale of Esaote SpA (Genova, Italy) to a consortium of investors led by Banca Intesa, including Prof. Carlo Castellano, current chairman and CEO of Esaote.

The transaction is part of Banca Intesa's strategy to sustain Italy's development by supporting entrepreneurs who invest in innovation and long-term growth by the acquisition of equity stakes. The sale of Esaote stems from a precise strategic decision for the Bracco Group headed by Diana Bracco: on the one hand, to focus on the development of new proprietary systems with a cutting-edge innovation content in the sector of diagnostics and targeted therapy; on the other hand, to further increase its competitive capacities on the global international markets in which Bracco competes.

Esaote, with a consolidated turnover exceeding 240 million euros--of which approximately 60% was generated in international markets--is the leader in Italy in the sector of biomedical appliances (specifically, ultrasound, targeted magnetic resonance [MR], and software to manage the diagnostic process). Esaote has its industrial and research units in Italy and the Netherlands, and in 2004 established a joint venture in China for the production of ecographic equipment, in which it has an 80% stake.

Corrado Passera, managing director and CEO of Banca Intesa SpA, commented, "Esaote is an extremely successful industrial and technological entity in the Italian research panorama. One of Banca Intesa's missions is to sustain Italian companies which are sound from an industrial standpoint, have considerable technological competencies, and are significant in terms of employment.”

Diana Bracco, chairman and managing director of Bracco SpA stated, "Over the years, the Bracco group has become the sole Italian global player in the sector of contrast methods for diagnostic imaging with market shares which are, on average, about 30% in the United States and Germany, and close to 50% in Italy and Japan.”




Related Links:
Banca Intesa
Bracco
Esaote
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Pressure Monitoring Mattress
Entrix NX
New
Facet Fixation System
ZYFUSE

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.